Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

PURPOSE: This trial assessed the safety, pharmacokinetics, and efficacy of darolutamide (ODM-201), a new-generation nonsteroidal androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: In this open-label, nonrandomized, two-cohort, do...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Chemother Pharmacol
Glavni autori: Matsubara, Nobuaki, Mukai, Hirofumi, Hosono, Ako, Onomura, Mai, Sasaki, Masaoki, Yajima, Yoko, Hashizume, Kensei, Yasuda, Masanobu, Uemura, Miho, Zurth, Christian
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2017
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5686265/
https://ncbi.nlm.nih.gov/pubmed/28801852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3417-3
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items